N-Zyme Biomedical announced the successful closing of its Series A financing, raising approximately $4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for reflux disease.

The financing was backed by a diverse group of investors, including healthcare professionals, entrepreneurs, a venture capital group, and strategic investors who recognize the significant unmet medical need in reflux disease and the potential of N-Zyme's differentiated scientific approach.